Compare CIF & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIF | NNVC |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 24.2M |
| IPO Year | N/A | 2008 |
| Metric | CIF | NNVC |
|---|---|---|
| Price | $1.64 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.4K | ★ 228.8K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.52 | $0.85 |
| 52 Week High | $1.82 | $2.23 |
| Indicator | CIF | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 45.50 |
| Support Level | N/A | $0.85 |
| Resistance Level | $1.73 | $1.07 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 66.52 | 24.00 |
Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.